Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Stock Traded 19.3% Above Its 50 Day Moving Average

0
32

Company shares last traded at $7.17 impressively higher than the 50 day moving average of $6.01 and just a bit lower than the 200 day moving average of $7.45. The 50 day moving average went up by +19.33% and the 200 day average went down by -3.70%. 1,717K shares changed hands in the last trading session. Trading volume was up 118.65% over the stocks average daily volume.

Traders are a little more bearish on Progenics Pharmaceuticals Inc. recently as indicated by the increase in short interest. The company recorded a rise in short interest of 4.16% between August 15, 2017 and August 31, 2017. Short interest grew 319,253 over that timeframe. Days to cover increased from 5.0 to 7.0 and the short interest percentage is 0.11% as of August 31.

The following firms have recently changed their position in PGNX. Squarepoint Ops LLC augmented its holdings by buying 40,833 shares an increase of 75.2% as of 06/30/2017. Squarepoint Ops LLC now holds 95,132 shares with a value of $646,000. The value of the position overall is up by 25.9%. As of the end of the quarter Pacad Investment Ltd. had disposed of 21,100 shares trimming its stake by 70.8%. The value in dollars decreased from $281,000 to $59,000 a change of $222,000 quarter over quarter.

As of quarter end Ubs Group Ag had sold a total of 9,017 shares trimming its position 75.5%. The value of the investment in (PGNX) went from $113,000 to $20,000 a change of 82.3% for the reporting period. As of the end of the quarter Mark Sheptoff Financial Planning, LLC had sold a total of 1 shares trimming its holdings by 9.1%. The value of the company’s investment in Progenics Pharmaceuticals Inc. decreased from $0 to $0 decreasing nan% quarter to quarter.

On July 12, 2017 Cantor Fitzgerald initiated coverage on PGNX with a rating of “Overweight”.

In the last earnings report the EPS was $-0.06 and is projected to be $-0.90 for the current year with 70,269,000 shares outstanding. Analysts expect next quarter’s EPS will be $-0.20 and the next full year EPS is anticipated to be $-0.36.

Progenics Pharmaceuticals, Inc., launched on December 1, 1986, is involved in developing medicines and other products for targeting and treating cancer. The Business’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation..